Drug Database · Clinicians

Lidocaine + Prilocaine

Also known as: lignocaine (former British name, for lidocaine)

Brands (8) Anesta, Combikane, Dermacaine…Show all

US brand (reference label): Oraqix; not a Philippine-registered brand.

Amide Local Anesthetic; Antiarrhythmic US FDA class
Local anesthetic (amide); Anesthetics; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug9 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b501d239-923b-48b2-82ed-6c5c253a67e2, version date April 21, 2026 (Oraqix · Dentsply Pharmaceutical). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Oraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Oraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing. Oraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing. (1)

Contraindications

4 CONTRAINDICATIONS Oraqix is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any other component of the product. A history of hypersensitivity to local anesthetics of the amide type (4) A history of hypersensitivity to any component of the product (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Use the included blunt-tipped applicator and the dispenser, which is sold separately, to apply gel to gingival margins and periodontal pockets. (2) May be reapplied as needed up to a maximum of 5 cartridges per treatment session.(2)

2.1 General Dosing Information DO NOT

2.1 General Dosing Information DO NOT INJECT [see Warnings and Precautions (5.2)] Apply Oraqix on the gingival margin around the selected teeth using the blunt-tipped applicator included in the package and the dispenser, which is sold separately. Wait 30 seconds, and then fill the periodontal pockets with Oraqix using the blunt-tipped applicator until the gel becomes visible at the gingival margin.

Wait another 30 seconds before starting treatment. A longer waiting time does not enhance the anesthesia. Anesthetic effect, as assessed by probing of pocket depths, has a duration of approximately 20 minutes (individual overall range 14–31 minutes). If the anesthesia starts to wear off, Oraqix may be re-applied if needed.

Typically, one cartridge (1.7g) or less of Oraqix will be sufficient for one quadrant of the dentition. When administered, Oraqix should be a liquid. If it has formed a gel, it should be placed in a refrigerator (do not freeze) until it becomes a liquid again. When in the liquid state, the air bubble visible in the cartridge will move if the cartridge is tilted.

2.2 Maximum Recommended Dosage

2.2 Maximum Recommended Dosage The maximum recommended dose of Oraqix at one treatment session is 5 cartridges, i.e., 8.5g gel.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Renal Impairment: Lidocaine and prilocaine and their metabolites are known to be excreted by the kidney, and the metabolites may accumulate in patients with impaired renal function.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Very young children are more susceptible to methemoglobinemia. There have been reports of clinically significant methemoglobinemia in infants and children following excessive applications of lidocaine 2.5% topical cream [See Warnings and Precautions (5.1)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects in clinical studies of Oraqix, 7% were aged 65 and over, while 1% were aged 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Dosage forms

Philippines

  • Per gram cream: 25 mg/25 mg
  • Per gram topical cream: 25 mg/25 mg
  • Cream: 25 mg/25 mg
  • Per g cream: 25 mg/25 mg

Registered products in the Philippines

9 products registered with the Food and Drug Administration (FDA) Philippines list Lidocaine + Prilocaine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products9
Philippine FDA-registered products for Lidocaine + Prilocaine
Package insert
AnestaLidocaine + Prilocaine
25 mg/25 mg per gram CreamAluminum collapsible tube x 5 g (Box of 1's)
Rx
Agio Pharmaceuticals Ltd.India
Ambica International Corporation.Importer: Ambica International Corporation
DRP-13668
Mar 23, 2028
CombikaneLidocaine + Prilocaine
25 mg/25 mg per gram CreamCollapsible Aluminum Tube x 5 g and 30 g (Box of 1's)
Rx
Yash Medicare Private LimitedIndia
Eon Pharmatek, Inc.Trader: I-Care Formulations
DR-XY43465
Jun 3, 2029
DermacaineLidocaine + Prilocaine
25 mg/25 mg per gram (2.5% 2.5%) Topical Cream30 g Aluminum Tube
Rx
Gruppo Medica, Inc.Philippines
Trader: Time Machine Cosmetiques, Inc.
DR-XY38589
Mar 8, 2028
EmlaLidocaine Hydrochloride + Prilocaine Hydrochloride
25 mg/25 mg (5%) CreamTube x 5 g (Box of 5's)
Rx
Meribel Pharma Karlskoga ABSweden
Importer: Aspen Philippines Inc.Trader: AstraZeneca AB
DR-XY3694
Aug 1, 2031
EmloprilLidocaine + Prilocaine
25 mg/25 mg per g (2.5%/2.5% w/w) CreamAluminum Collapsible Tube x 10 g and 30 g (Box of 1’s)
Rx
Genuone Sciences Inc.Republic of Korea
International Apex Pharmaceuticals, Inc.
DR-XY39759
Jul 13, 2031
NoneLidocaine/ Prilocaine
25 mg / 25 mg per gram (5% w/w) CreamAluminum collapsible tube (in a box) x 5 g and 30 g
Rx
Amherst Laboratories, Inc.Philippines
—
DR-XY46188
Dec 8, 2027
PrilocLidocaine + Prilocaine
25 mg/25 mg per gram (2.5%/2.5% w/w) Topical CreamLaminated tube x 5g, 10 g, and 30 g
Rx
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-15983
Oct 8, 2029
SkinumbLidocaine + Prilocaine
25 mg/25 mg per gram CreamLaminated tube x 5 g, 10 g, and 30 g (Box of 1’s)
Rx
Sava Healthcare Ltd.India
Ambica International Corporation
DRP-9777
Jun 7, 2031
XylocreamLidocaine + Prilocaine
25 mg/25 mg per gram (2.5%/2.5 % w/w) Topical CreamAluminum collapsible tube x 5 g (Box of 5's) Aluminum collapsible tube x 30 g (Box of 1's)
Rx
Rafarm S.A.Greece
Raquel-Abbas Pharmaceuticals & General MerchandiseTrader: Verisfield (UK) Ltd.
DRP-12833
Oct 12, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Periodontal gel containing: lidocaine 25 mg/mL and prilocaine 25 mg/mL. Each cartridge contains 1.7 mL (42.5 mg of lidocaine and 42.5 mg of prilocaine). Periodontal gel containing: lidocaine 25 mg/mL and prilocaine 25 mg/mL. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. (5.1)
  • DO NOT INJECT (5.2)
  • Allergic and anaphylactic reactions can occur (5.3)
  • Avoid contact with eyes (5.4)
  • Use with caution in patients with severe hepatic disease (5.6)
5.1 Methemoglobinemia

5.1 Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition.

If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death.

Discontinue ORAQIX and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

5.2 DO NOT

5.2 DO NOT INJECT Oraqix should not be used with standard dental syringes. Only use this product with the Oraqix blunt-tipped applicator and the dispenser which is available from DENTSPLY Pharmaceutical.

5.3 Allergic/anaphylactic

5.3 Allergic/anaphylactic reactions Allergic and anaphylactic reactions associated with lidocaine or prilocaine in Oraqix can occur. These reactions may be characterized by urticaria, angioedema, bronchospasm, and shock. If these reactions occur they should be managed by conventional means.

5.4 Avoid Contact with Eyes

5.4 Avoid Contact with Eyes Oraqix coming in contact with the eye should be avoided because animal studies have demonstrated severe eye irritation. A loss of protective reflexes may allow corneal irritation and potential abrasion. If eye contact occurs, immediately rinse the eye with water or saline and protect it until normal sensation returns.

In addition, the patient should be evaluated by an ophthalmologist, as indicated.

5.5 History of Drug Sensitivity

5.5 History of Drug Sensitivity Patients allergic to paraminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine and/or prilocaine. However, Oraqix should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain.

5.6 Severe Hepatic Disease

5.6 Severe Hepatic Disease Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations of lidocaine and prilocaine.

Drug interactions

Drug interactions (US label) US FDA label
  • Other local anesthetics or agents structurally related to local anesthetics (7.1)
  • Drugs That May Cause Methemoglobinemia When Used With ORAQIX (7.2)
7.1 Other Local Anesthetics or Agents Structurally Related to Local

7.1 Other Local Anesthetics or Agents Structurally Related to Local Anesthetics Oraqix should be used with caution in combination with dental injection anesthesia, other local anesthetics, or agents structurally related to local anesthetics, e.g., Class 1 antiarrhythmics such as tocainide and mexiletine, as the toxic effects of these drugs are likely to be additive and potentially synergistic.

7.2 Drugs That May Cause Methemoglobinemia When Used With

7.2 Drugs That May Cause Methemoglobinemia When Used With ORAQIX Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

The main metabolism of lidocaine is through N-dealkylation to monoethylglycinexylidide (MEGX) and glycinexylidide (GX), which is mainly mediated by CYP3A4.

These metabolites are hydrolyzed to 2,6-xylidine, which is converted to 4-hydroxy- 2,6-xylidine (mediated by CYP2A6), the major urinary metabolite in man.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS Most common adverse reactions (incidence >15%) are application site reactions including pain, soreness, irritation, numbness, ulcerations, vesicles, edema, abscess and/or redness. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact DENTSPLY Pharmaceutical at 1-800-989- 8826 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Although no major differences in adverse events between Oraqix and placebo-treated subjects were observed, all patients in the placebo-controlled studies received either Oraqix or a placebo gel (consisting of the vehicle in Oraqix without lidocaine or prilocaine). Therefore, it is not possible to determine if adverse events in each treatment group were attributable to the inactive ingredients comprising the Oraqix or vehicle or if adverse event rates were higher than expected background rates.

Therefore, a causal relationship between the reported adverse reactions and Oraqix could neither be established nor ruled out. Following SRP treatment with Oraqix in 391 patients, the most frequent adverse events were local reactions in the oral cavity (see following table). These events, which occurred in approximately 15% of patients, included pain, soreness, irritation, numbness, vesicles, ulcerations, edema and/or redness in the treated area.

Of the 391 patients treated with Oraqix, five developed ulcerative lesions and two developed vesicles of mild to moderate severity near the site of SRP. In addition, ulcerative lesions in or near the treated area were also reported for three out of 168 patients who received placebo. Other symptoms reported in more than one patient were headache, taste perversion, nausea, fatigue, flu, respiratory infection, musculoskeletal pain and accident/injury.

Table 1. Number (percent) of patients with adverse events occurring in more than one patient in any of the treatment groups. Each patient is counted only once per adverse event. The occurrence in a single patient is included in this table if the same symptom has been seen in at least one patient in another group. System Organ Class PreferredTerm Oraqix gel in a cross-over study, 170 subjects received either Oraqix or lidocaine injection 2% in each test period (N=391)n (%) Placebo gel (N=168)n (%) Lidocaine injection (N=170)n (%) Muscular-Skeletal System Disorders Myalgia 1(0) 2(1) Arthralgia and/or Arthropathy 1(0) 1(1) Central & Peripheral Nervous System Disorders Headache 8(2) 3(2) 5(3) Dizziness 1(0) 1(1) 1(1) Special Senses Other, Disorders Taste Perversion includes complaints of bad or bitter taste lasting for up to 4 hours after administration of Oraqix 8(2) 1(1) Gastro-Intestinal System Disorders Nausea 3(1) 1(1) Respiratory System Disorders Respiratory Infection 2(1) 1(1) Rhinitis 2(1) Body as a whole-General Disorders Accident and/or Injury 2(1) 2(1) Fatigue 3(1) 2(1) Flu-Like Disorder 2(1) Pain (remote from application site) 1(0) 1(1) 1(1) Application Site Disorders i.e. symptoms in the oral cavity Anesthesia Local 2(1) Application Site Reaction includes pain, soreness, irritation, numbness, ulcerations, vesicles, edema, abscess and/or redness in the treated area 52(13) 20(12)

Adverse reaction frequency tables (US label) US FDA label
Table 1. Number (percent) of patients with adverse events occurring in more than one patient in any of the treatment groups.
Each patient is counted only once per adverse event. The occurrence in a single patient is included in this table if the same symptom has been seen in at least one patient in another group.
System Organ Class PreferredTermOraqix gelin a cross-over study, 170 subjects received either Oraqix or lidocaine injection 2% in each test period (N=391)n (%)Placebo gel (N=168)n (%)Lidocaine injection (N=170)n (%)
Muscular-Skeletal System Disorders Myalgia1(0)2(1)
Arthralgia and/or Arthropathy1(0)1(1)
Central & Peripheral Nervous System Disorders
Headache8(2)3(2)5(3)
Dizziness1(0)1(1)1(1)
Special Senses Other, Disorders Taste Perversionincludes complaints of bad or bitter taste lasting for up to 4 hours after administration of Oraqix8(2)1(1)
Gastro-Intestinal System Disorders Nausea3(1)1(1)
Respiratory System Disorders Respiratory Infection2(1)1(1)
Rhinitis2(1)
Body as a whole-General Disorders Accident and/or Injury2(1)2(1)
Fatigue3(1)2(1)
Flu-Like Disorder2(1)
Pain (remote from application site)1(0)1(1)1(1)
Application Site Disordersi.e. symptoms in the oral cavity Anesthesia Local2(1)
Application Site Reactionincludes pain, soreness, irritation, numbness, ulcerations, vesicles, edema, abscess and/or redness in the treated area52(13)20(12)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Pregnancy Category B .Reproduction studies have been performed in rats with lidocaine, prilocaine and a 1:1 (weight:weight) mixture of the two compounds. There was no evidence of harm to the fetus at subcutaneous doses of up to 30 mg/kg lidocaine (estimated exposure was approximately equivalent to the expected lidocaine exposure at the maximum recommended human dose of Oraqix (lidocaine and prilocaine periodontal gel) 2.5% / 2.5% on a mg/m 2 basis).

Following intramuscular prilocaine doses of up to 300 mg/kg (estimated exposure was approximately 11 times the expected prilocaine exposure at the maximum recommended human dose of Oraqix gel on a mg/m 2 basis), there was no evidence of impaired fertility or harm to the fetus. Similarly, subcutaneous administration of a lidocaine and prilocaine mixture of 40 mg/kg of each compound (estimated exposures were approximately 1.5 times the expected lidocaine and prilocaine exposures at the maximum recommended human dose of Oraqix gel on a mg/m 2 basis) produced no teratogenic, embryotoxic, or fetotoxic effects.

Reproductive toxicology studies of lidocaine were also conducted in rabbits. There was no evidence of harm to the fetus at a dose of 5 mg/kg, s.c. (60 mg/m 2). Treatment of rabbits with 15 mg/kg (180 mg/m 2) produced evidence of maternal toxicity and evidence of delayed fetal development, including a non-significant decrease in fetal weight (7%) and an increase in minor skeletal anomalies (skull and sternebral defects, reduced ossification of the phalanges).

The effects of lidocaine and prilocaine on post-natal development was examined in rats treated for 8 months with 10 or 30 mg/kg, s.c. lidocaine or prilocaine (60 mg/m 2 and 180 mg/m 2 on a body surface area basis, respectively up to 1.4-fold the maximum recommended exposure for a single procedure). This time period encompassed 3 mating periods.

There was no evidence of altered post-natal development in any offspring; however, both doses of either drug reduced the average number of pups per litter surviving until weaning of offspring from the first 2 mating periods. In a separate study, the effect of prilocaine on pre- and postnatal development was examined in rats treated with up to 60 mg/kg, s.c.

(up to 2.8 times the maximum recommended human dose of prilocaine in Oraqix gel on a mg/m 2 basis) from Day 6 of gestation to weaning. There was no evidence of altered post-natal development, viability, or reproductive capacity in any offspring. All the above calculations of exposure are assuming 100% bioavailability of lidocaine and prilocaine after Oraqix administration.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Oraqix should be used during pregnancy only if the benefits outweigh the risks. Reproduction studies on the Oraqix drug product, including the inactive ingredients, have not been conducted.

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Nursing Mothers Lidocaine and, possibly, prilocaine are excreted in breast milk. Caution should be exercised when Oraqix is administered to nursing women.

Mechanism of action

12.1 Mechanism of Action Lidocaine and prilocaine belong to the amide class of local anesthetics. Both lidocaine and prilocaine block sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics After application of Oraqix on the gingival margin and a waiting period of 30 seconds, additional Oraqix is applied directly into periodontal pockets to provide localized anesthesia. The onset of local anesthetic effect after application of Oraqix into the periodontal pocket occurs by 30 seconds and a longer waiting time does not enhance the anesthetic affect. Anesthetic effect, as assessed by probing of pocket depths, lasted for about 20 minutes (individual overall range 14 to 31 minutes).

Pharmacokinetics

Half-life and elimination (verbatim, US label)

These metabolites are hydrolyzed to 2,6-xylidine, which is converted to 4-hydroxy- 2,6-xylidine (mediated by CYP2A6), the major urinary metabolite in man.

MEGX has an antiarrhythmic and convulsant activity similar to that of lidocaine and a somewhat longer half-life.

GX has a weak antiarrhythmic effect but lacks convulsant activity and has a half-life of about 10 h.

The prilocaine metabolite o-toluidine and the hydroxylated metabolites of o-toluidine are excreted mainly in the urine. o-Toluidine has been shown to be carcinogenic in several animal models.

The terminal half-life of both drugs after intravenous administration as single agents is 1.6 h.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption: Lidocaine and prilocaine are absorbed from Oraqix via the oral mucous membranes. After a single application of 0.9 to 3.5 g Oraqix, the mean (±SD) lidocaine and prilocaine Cmax values were 182 (±53) and 77 (±27) ng/mL, respectively. After a total of 8 to 8.5 g Oraqix administered as repeated applications over 3 hours, the mean (±SD) lidocaine Cmax was 284 (±122) ng/mL, ranging between 157 and 552 ng/mL.

The mean lidocaine AUC∞ was 84,000 ng/min/mL. The mean (±SD) prilocaine Cmax was 106 (±45) ng/mL, ranging between 53 and 181 ng/mL. The mean prilocaine AUC∞ was 26,000 ng/min/mL. The increase in Cmax of both lidocaine and prilocaine is proportional (or less than proportional) to the dose after single application of Oraqix.

The Cmax after a cumulative dose of 8.5 g Oraqix administered as repeated applications over 3 hours, (i.e. the highest recommended dose, corresponding to 212.5 mg each of lidocaine and prilocaine base), is lower than that extrapolated from the proportional increase in plasma concentrations at lower doses. The median Tmax of lidocaine and prilocaine was 30 minutes, ranging between 20 and 40 min., after the start of a single application of 0.9 to 3.5 g Oraqix, and 200 minutes, ranging between 120 and 200 min., after a cumulative dose of 8.5 g Oraqix administered as repeated applications over 3 hours.

The toxicities of lidocaine and prilocaine are thought to be additive. Systemic CNS toxicity may occur over a range of plasma concentrations of local anesthetics. CNS toxicity may typically be found around 5000 ng/mL of lidocaine, however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL.

Pharmacological thresholds for prilocaine are poorly defined. Distribution: Lidocaine and prilocaine have an intermediate degree of plasma protein binding, mainly to 1-acid glycoprotein, with a protein binding of 70% and 40%, respectively. When administered intravenously, the mean volume of distribution (for 60 kg person) at steady state for lidocaine and prilocaine were 90 L and 156 L, respectively.

Oraqix is not intended for intravenous administration. Both lidocaine and prilocaine cross the placental and blood brain barriers, presumably by passive diffusion. Metabolism: Lidocaine and prilocaine are mainly metabolized in the liver. Prilocaine and lidocaine are not metabolized by plasma esterases. The main metabolism of lidocaine is through N-dealkylation to monoethylglycinexylidide (MEGX) and glycinexylidide (GX), which is mainly mediated by CYP3A4.

These metabolites are hydrolyzed to 2,6-xylidine, which is converted to 4-hydroxy- 2,6-xylidine (mediated by CYP2A6), the major urinary metabolite in man. After a total of 8 to 8.5g Oraqix administered as repeated applications over 3 hours, the mean (+SD) 2,6-xylidine Cmax was 18 (+8.4) ng/mL ranging between 8 and 32 ng/mL.

The mean 2,6-xylidine AUC∞ was 9800 ng/min/mL (±6370), ranging between 3480 to 24,580 ng/min/mL). MEGX has an antiarrhythmic and convulsant activity similar to that of lidocaine and a somewhat longer half-life. GX has a weak antiarrhythmic effect but lacks convulsant activity and has a half-life of about 10 h. Prilocaine is split at the amide linkage to o-toluidine, which is converted further to 4- and 6- hydroxytoluidine.

The prilocaine metabolite o-toluidine and the hydroxylated metabolites of o-toluidine are excreted mainly in the urine. o-Toluidine has been shown to be carcinogenic in several animal models. After a total of 8 to 8.5g Oraqix was administered as repeated applications over 3 hours, the mean (±SD) o-toluidine Cmax was 25 (±11) ng/mL ranging between 13 and 44 ng/mL.

The mean o-toluidine AUC∞ was 9200 ng/min/mL. The median Tmax was 220 minutes, ranging between 90 and 240 min. In addition, o-Toluidine can cause the formation of methemoglobin (metHb) following treatment with prilocaine. Individual maximum blood concentrations of metHb increased from 0 to 1.1% up to 0.8 to 1.7% following administration of the maximum recommended dose of 8.5g Oraqix administrated as repeated applications over 3 hours.

The Tmax of metHb ranged from 1 to 4 hours. Normally, <1 % of the total hemoglobin is in the form of metHb. [See OVERDOSAGE (10)]. Patients with glucose-6-phosphate dehydrogenase deficiencies, and patients taking oxidizing drugs such as antimalarials and sulfonamides are more susceptible to drug-induced methemoglobinemia. [See Warnings and Precautions (5.1)].

Elimination: Lidocaine and prilocaine have systemic clearances of 0.95 and 2.37 L/min, respectively, after intravenous administration as single agents. The terminal half-life of both drugs after intravenous administration as single agents is 1.6 h. Oraqix is not intended for intravenous administration. However, after application of Oraqix to the periodontal pockets the mean (±SD) terminal lidocaine half-life was 3.6 (±1.3)hours, ranging between 2.2 and 6.5 h.

The mean (±SD) terminal prilocaine half-life was 2.8 (±1.0) hours, ranging between 2.0 to 5.7 h. For the metabolite o-toluidine the mean terminal half-life was 4.0 (±1.1) hours, ranging between 2.0 and 5.7 hours. For the metabolite 2,6-xylidine the mean terminal half-life was 8.0 (±4.0) hours, ranging between 3.7 and 18.3 hours.

Pediatrics: The pharmacokinetics of lidocaine and prilocaine after Oraqix administration have not been studied in pediatric patients. Geriatrics: The pharmacokinetics of lidocaine and prilocaine after Oraqix administration have not been studied in geriatric patients. However, intravenous studies, the elimination half-life of lidocaine was statistically significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours).

No studies in the intravenous pharmacokinetics of prilocaine in elderly patients have been performed. Special populations: No pharmacokinetic studies were conducted to specifically address special populations. Renal Impairment: Lidocaine and prilocaine and their metabolites are known to be excreted by the kidney, and the metabolites may accumulate in patients with impaired renal function.

Hepatic Impairment: The half-life of lidocaine may be prolonged two-fold or more in patients with liver dysfunction. Liver dysfunction may also alter prilocaine pharmacokinetics. Because of their inability to metabolize local anesthetics normally, patients with severe hepatic disease, are at a greater risk of developing toxic plasma concentrations of lidocaine and prilocaine.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Oraqix · Dentsply Pharmaceutical [US FDA-approved label, version 12, April 21, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .